SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

05 фев 2025 08:45:03 Источник NetDania Notify

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

04 фев 2025 11:22:34 Источник NetDania Notify

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

04 фев 2025 08:00:05 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

30 янв 2025 08:45:48 Источник NetDania Notify

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

28 янв 2025 10:23:40 Источник NetDania Notify

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

27 янв 2025 09:40:08 Источник NetDania Notify

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

27 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

26 ноя 2024 16:00:18 Источник Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

13 ноя 2024 15:30:46 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

05 ноя 2024 08:45:03 Источник NetDania Notify

Supernus Announces Third Quarter 2024 Financial Results

04 ноя 2024 15:05:00 Источник Nasdaq GlobeNewswire

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

31 окт 2024 15:10:46 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK

30 окт 2024 14:07:03 Источник NetDania Notify

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

21 окт 2024 15:25:48 Источник Nasdaq GlobeNewswire

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

17 окт 2024 15:05:25 Источник Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

10 окт 2024 16:12:14 Источник Nasdaq GlobeNewswire

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

24 сен 2024 06:30:33 Источник Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

19 сен 2024 15:30:44 Источник Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

28 авг 2024 15:15:26 Источник Nasdaq GlobeNewswire

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

19 авг 2024 06:00:51 Источник Nasdaq GlobeNewswire